NEW YORK, Sept. 11, 2026 - 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026 via Gains in the United States and Other Strategic Markets
Baird Medical Investment Holdings (Nasdaq: BDMD), an emerging global med-tech company working to transform minimally invasive ablation technology, has announced preliminary unaudited financial results for the six months ended June 30, 2026.
BDMD revenue for the first half of 2026 was approximately $9.9 million, an increase of 24.6% over $8.0 million reported for the six months ended June 30, 2025. The increase in revenue was primarily attributable to growth outside of the People’s Republic of China, including in the United States, as well as licensing revenue. Approximately two thirds of revenue for the period was generated from markets outside of the PRC, with Hong Kong and the U.S. being the main contributing regions.
BDMD gross profit for the period was $8.6 million, an increase of 32.0% compared to $6.5 million in the first half of 2025. Gross margin was 87.0% for the six months ended June 30, 2026, compared to 82.1% for the prior-year period. The increase in gross margin was primarily attributable to shifts in both the geographic breakdown of sales and revenue mix.
BDMD achieved approximately $1.6 million in EBITDA, with adjusted EBITDA of approximately $4.0 million for the first half of 2026. This compares with EBITDA and adjusted EBITDA of $(9.7) million and $(3.3) million in same period last year.
Expanding Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan
BDMD has announced that its BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”).
The registrations build on the BDMD existing presence in Pakistan, where the Company announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging (“AFIRI”) in January 2026. The latest registrations further expand the regulatory foundation supporting the availability and use of BDMD microwave ablation technology in the market.
MWA is increasingly being utilized as a minimally invasive treatment approach for benign and malignant soft tissue tumors, offering physicians the ability to precisely ablate targeted tissue while potentially reducing the burden associated with more invasive surgical procedures. As awareness and adoption of image-guided ablation continue to develop in the United States and internationally, BDMD is focused on expanding the regulatory, commercial and clinical infrastructure supporting broader physician and patient access to its technology.
The registrations represent continued progress in the BDMD international expansion strategy as the Company advances regulatory and commercial development of its minimally invasive ablation technologies across key global markets.
BDMD has established a commercial footprint, while continuing to further establish its presence in the United States. Earlier this year, physicians in Vietnam and Argentina successfully completed their first microwave ablation procedures using BDMD technology, demonstrating the progression from market entry to clinical utilization. The additional registrations in Pakistan further support this momentum as BDMD works to broaden physician and patient access to MWA technology across global markets.
Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally
BDMD and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand, a China-based innovator in irreversible electroporation (“IRE”) technology, announced the signing of a strategic cooperation agreement to establish a long-term partnership focused on global development and commercialization of next-generation IRE technologies.
The partnership represents an important strategic milestone for BDMD, as the Company expands beyond its market-leading microwave ablation (MWA) system for benign thyroid nodules and broadens its portfolio of minimally invasive technologies targeting key markets worldwide.
BDMD and Alpmed will initially collaborate on IRE, an advanced, non-thermal ablation technology that uses electrical pulses to destroy targeted tissue while preserving surrounding critical structures, such as blood vessels and nerves. The collaboration will combine Alpmed's expertise in IRE innovation with BDMD regulatory and global commercialization capabilities, with the goal of advancing next-generation precision ablation solutions and exploring opportunities to expand the partnership beyond IRE.
BDMD and Alpmed plan to submit a 510(k) application for the first co-developed product to the U.S. Food and Drug Administration (FDA) by the end of 2026, with the potential to receive regulatory clearance in 2027. The first device is intended for the ablation of soft tissue solid tumors in the liver, breast, thyroid, and prostate. BDMD will lead the global regulatory approval processes, including in the U.S., and holds worldwide commercialization rights for this IRE product.
25% Revenue Growth and Positive Net Income for Six Months of 2026.
Significant Gains in the United States and Other Strategic Markets.
Expanding Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan.
Registrations Cover the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle.
Strategic Partnership with Alpmed to Advance Irreversible Electroporation (IRE) Technology Globally.
Collaboration to Advance Development, Regulatory Approvals, Commercialization and Clinical Adoption Across Key International Markets, Including the USA.
Physicians in Vietnam and Argentina Have Successfully Completed Their First Microwave Ablation Procedures Using BDMD Technology.
--------------------------------------------------------------------------------------------------------------------
About Baird Medical Investment Holdings Ltd.
Baird Medical Investment Holdings Ltd. (Nasdaq: BDMD) is an emerging global med-tech company attempting to transform minimally invasive ablation, starting with microwave ablation into a broader platform incorporating international commercialization, IRE technology, AI and robotics.
Mission
Baird Medical's stated vision is particularly interesting: it aims to build a global precision-thyroid-health platform spanning the treatment process from early screening and diagnosis through robotic-assisted ablation and post-treatment care. In simpler terms, the company wants to make minimally invasive treatment safer, faster and more precise, while combining medical-device hardware with intelligent software and eventually robotic technology.
Baird Medical Investment Holdings Limited was incorporated as a Cayman Islands exempted companyon June 16, 2023. This is the corporate entity behind the current Nasdaq-listed company. On October 2, 2024 BDMD began trading on Nasdaq, following completion of its business combination.
For more information on BDMD visit: https://ir.bairdmed.com/ or https://www.compasslivemedia.com/bdmd/
Email: Lroth@burnsmc.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: Baird Medical Investment Holdings Ltd. (Nasdaq: BDMD)
Contact Person: Lee Roth, Burns McClellan for Baird Medical
Email: Send Email
Phone: (86) 20 8218-5926
Address:Baide Building, Building 11 Room 202, 2/F No.15 Rongtong Street, Yuexiu District Guangzhou China
Country: China
Website: https://ir.bairdmed.com/
